3. CD34 analysis, CFU-GM culture. 
4. Bone marrow aspirate for pathology, CFU-GM, CD34 analysis (Dr. Bensinger 
AC 134) and for Dr. Torok-Storb (1-2 ml heparinized marrow to 766, attn: Dr. 
Torok-Storb). 
5. Pretransplant preparative regimen. 
C. Day of Transplantation fdav 01 
1. Bone marrow infusion. 
2. Peripheral blood cell infusion. 
3. Begin administration of rhG-CSF. 
D. Post Marrow Transplantation (daily from day 0 to day 201 . 
1. Administer rhG-CSF (total of 21 days only). 
2. Perform hematologic assays. 
3. Perform clinical evaluation. 
E. Post Marrow Transplantation (day 21 to day 281 
1. As long as patient is in the hospital, perform steps D.2 to D.4 above. 
2. If patient is discharged from the hospital before day 28, measure temperature^ 
hematologic assays and clinical evaluation at least 3x/week unless patients’ 
condition requires more frequent assays. 
F. Post Marrow Transplantation (day 28 to day 100. end of study) 
1. While patient is still in the hospital, unless patients’ condition requires greater 
frequency: 
a) Vital signs daily. 
b) 3x/week cellular hematologic assays and cnmcai evaluations. 
2. Once discharged from hospital, unless patients’ condition requires a greater 
frequency: 
a) Vital signs, cellular hematologic assays and clinical evaluation 3x/week 
until day 35, then once/week. 
b) Bone marrow assays for pathology on day 56 and 84. 
G. At the End of the Study (DAY 1001 
Record engraftment status, relapse, survival. 
H. At 1 Year Posttransplantation: 
Record engraftment status, relapse, survival. 
Definition and Measurement of Toxicity 
A. Toxicity related to G-CSF is minimal. No life threatening toxicides have been identified 
in over 50 patients at doses similar to those defined in this study. Minor and rare 
toxicides in occasional padents have included low grade temperature elevations, 
headaches, nausea and myalgias. 
B. In 29 consecutive patients treated with cyclophosphamide/TBI in autologous 
transplantation and in the last 45 padents undergoing autologous BMT at the FHCRC 
who received rhGM-CSF, less than 20% develop grade III or IV regimen related toxicity. 
[350] 
Recombinant DNA Research, Volume 16 
